India's Cipla to make and sell Eli Lilly's baricitinib to treat COVID-19 – Reuters

India’s Cipla to make and sell Eli Lilly’s baricitinib to treat COVID-19 – Reuters

Indian drugmaker Cipla Ltd said on Monday it had entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly’s arthritis drug baricitinib for the treatment of COVID-19 patients.

Read More…

You May Also Like